Telmisartan

Telmisartan treats hypertension alone or with other antihypertensives. Its separate cardiovascular indication reduces myocardial infarction, stroke, or cardiovascular death risk in adults age 55 or older at high risk who cannot take an ACE inhibitor. High risk includes established coronary/peripheral arterial disease, stroke/TIA, or diabetes with end-organ damage. It supplements other risk management. The label advises considering an ACE inhibitor first, including possible re-trial after cough resolves, and does not claim telmisartan unequivocally preserves all ACE-inhibitor benefit.

This reference covers human single-ingredient oral telmisartan tablets. Pediatric efficacy is not established. Combination products with hydrochlorothiazide or amlodipine, veterinary telmisartan liquids, and unverified off-label regimens require their own evidence and are not included.

Take with or without food. Individualize hypertension dosing and concomitant medicines; most antihypertensive effect appears within 2 weeks and maximum effect around 4 weeks.

Correct salt/volume depletion before starting or use a reduced dose under close supervision. No initial adjustment is required for older age or renal impairment, including hemodialysis; monitor dialysis patients for orthostasis. Biliary obstruction or hepatic insufficiency requires a low start and slow titration; the label does not give a universal numeric hepatic regimen. Reassess other BP-lowering medicines when starting cardiovascular-prevention treatment.

Known hypersensitivity to telmisartan or a product component, including prior anaphylaxis or angioedema, is contraindicated. Aliskiren coadministration is contraindicated in patients with diabetes. Avoid aliskiren with renal impairment (GFR below 60 mL/min/1.73 m²); this is a separate avoid instruction, not a universal contraindication to telmisartan itself.

Renin–angiotensin system medicines can injure or kill the developing fetus. Discontinue telmisartan as soon as pregnancy is detected and arrange appropriate alternative hypertension management.

Hypertension trials reported upper respiratory infection, back pain, sinusitis, diarrhea, and pharyngitis more often than placebo, without proving causation for every event. Important postmarketing reports include angioedema/anaphylaxis, renal failure, hyperkalemia, syncope, liver disorders, and rare rhabdomyolysis; reporting cannot establish frequency. Excess dosing can cause hypotension, dizziness, tachycardia, or bradycardia and requires supportive assessment. Telmisartan is not removed by dialysis or hemofiltration.

Avoid usual combined RAS blockade and observe the aliskiren restrictions. Potassium supplements, potassium-containing salt substitutes, potassium-sparing diuretics, and other potassium-raising drugs increase hyperkalemia risk. NSAIDs, including COX-2 inhibitors, can reduce BP response and worsen renal function, especially in older, volume-depleted, or renally impaired patients; monitor renal function periodically.

Check digoxin levels when telmisartan is started, adjusted, or stopped; the label reports median peak and trough increases of 49% and 20%. Monitor lithium levels because concentrations and toxicity may increase. Other antihypertensives and diuretics can add hypotension and may require adjustment. Telmisartan is not metabolized through CYP450; this does not eliminate its pharmacodynamic or narrow-index interactions.

Stop promptly upon pregnancy detection. Later-pregnancy RAS blockade can cause oligohydramnios, fetal lung/skull abnormalities, neonatal hypotension, anuria, renal failure, or death; monitor exposed infants as indicated. Human milk/infant-effect data are absent in the label. Because serious infant effects are possible, it advises against breastfeeding during treatment; arrange a suitable alternative or feeding plan.

Pediatric safety and efficacy are not established, and pharmacokinetics below age 18 were not studied in this label. Older adults did not show overall trial differences, but greater individual sensitivity remains possible. No automatic age-based start adjustment is required; volume depletion, orthostasis, kidney function, and concurrent treatment guide caution.

No initial renal dose adjustment is required, including dialysis, but renal injury and potassium elevation remain possible and require monitoring. High protein binding prevents dialysis removal. Biliary obstruction/hepatic insufficiency raises exposure: start low, monitor, and increase slowly without inventing a numeric impairment table.

Telmisartan blocks angiotensin II binding at AT1 receptors, reducing vasoconstriction and aldosterone-related effects. It does not inhibit ACE or directly block bradykinin breakdown. This mechanism still carries fetal, renal, potassium, and hypotension risks.

Peak concentrations occur about 0.5–1 hour after oral dosing, with a terminal half-life near 24 hours. Binding exceeds 99.5%. Exposure is nonlinear and dose-dependent; food modestly reduces absorption but labeled use allows either meal state. Elimination is predominantly unchanged drug through bile into feces, with little urinary excretion. An inactive glucuronide forms without CYP450 metabolism; hepatic impairment markedly increases exposure.

Assess BP and volume status at initiation and during titration, including orthostatic symptoms in dialysis or vulnerable older patients. Follow renal function and electrolytes, especially with renal disease, potassium-raising drugs, NSAIDs, or other RAS agents. Monitor digoxin and lithium when relevant. Reassess hypertension response over the first 2–4 weeks and cardiovascular-prevention eligibility separately; the label does not supply a universal laboratory interval.

Report pregnancy immediately and discuss alternatives before conception. Do not breastfeed while taking this product without arranging a different plan. Rise carefully; report fainting or severe dizziness and contact the team during vomiting, diarrhea, or poor intake. Avoid potassium supplements or potassium salt substitutes unless approved, and discuss OTC NSAIDs. Facial/throat swelling or breathing difficulty needs emergency help. Keep tablets in the bottle until taking them.

Alembic telmisartan tablets are white to off-white and uncoated: 20 mg round, flat/beveled, marked L202; 40 mg oval/biconvex marked L203; 80 mg oval/biconvex marked L204. The reverse is plain. Child-resistant bottles of 30 have NDCs 62332-087-30, 62332-088-30, and 62332-089-30 respectively. Other manufacturers and brand packaging vary.

The selected product is an oral single-ingredient tablet in 20, 40, and 80 mg strengths. Combination tablets and veterinary liquids are separate products; neither their directions nor their concentration should be extrapolated to these tablets.

Store at 20–25°C (68–77°F), with permitted excursions to 15–30°C (59–86°F). Leave tablets in their bottle until immediately before administration. Follow the dispensed manufacturer’s label; brand blister instructions are not assumed for this generic bottle.